This site uses cookies. To find out more about cookies and how to manage them please see our Cookie policy.
By using this website you agree to cookies being placed on your device.

Inhaled mannitol provides rapid mucociliary clearance1 and early effect2,3

Early inhaled mannitol studies

1 hour

Significant improvement in bronchial mucus clearance in the first
60 minutes after inhaled mannitol (300mg*) administration (p=0.01 vs control)1

2 weeks

Significant improvement in FEV1 after 2 weeks (p<0.001 vs baseline)2, with a 420mg* twice daily dose

Phase 3 Bronchitol trials

6 weeks

Response at week 6 is highly predictive of long term FEV1 improvement over 26 weeks4

* The Licensed Dose of Bronchitol is 400mg twice daily.

1.Robinson M et al. Eur Respir J 1999; 14: 678-685. 2.Jaques A et al. Chest 2008; 133: 1388-96. 3.Teper A et al. Journal of Cystic Fibrosis 2011; 10: 1–8. 4.Pharmaxis data on file 8 - sc01plt7_204 - Scatter plot of correlation predicting response over 26 weeks.

Adverse events should be reported to Pharmaxis Ltd by email: adverse.events@pharmaxis.com.au.